Subject Index, 1980
Vol. 30, Nos. 1–6

A

Actinomycin-D
And mucocutaneous reactions to, 144–146, 150, 152
For ovarian cancer, 14
For rhabdomyosarcoma, 189
For testicular cancer, 252

Adriamycin
For acute lymphocytic leukemia (ALL), 170–171
Adverse reactions to, 170
And antiemetic for, 279–280
And mucocutaneous reactions to, 144–146, 148, 150–153
For ovarian cancer, 10, 14
For testicular cancer, 252

Aging, and cancer
Clinical considerations of, 338–339
Drug effects in, 344–345
Incidence of, 337, 339
Management of, 337–347 (See also, Radiation therapy)
Physiological changes in, 337–338, 341
Psychosocial problems of, 344–346
Sexual functions in, 344
Survival rates for, 338

Allopurinol
For acute lymphocytic leukemia (ALL), 164–165

American Cancer Society (ACS) cancer-related checkup guidelines
For breast cancer, 195–196, 224–231
For cervical cancer, 195–196, 215–223, 230–231
For colon and rectum cancer, 195–196, 208–215, 230–231
Cost-effectiveness analysis of, 197–198
Design issues of, 196–198
Experimental biases of, 234–236
Introduction to, 194
For lung cancer, 195–196, 199–207, 230–231
For populations *vs* individuals, 198
Previous ACS guidelines for, 199, 208, 215–216, 224
Rationale for, 205–206, 212–214, 219–223, 228–229
References for, 237–240
Risks and costs involved in, 202–205, 210–212, 218–219, 226–228
Summary of, 195–196, 229–234 (See also, specific sites and modalities)

Angiography, in diagnosis of childhood brain tumors, 308, 314

Anorexia, in the cancer patient, 110

Antiemetics
For cancer chemotherapy,
Prochlorperazine, 279, 283–284
THC (delta-9-tetrahydrocannabinol), 278–285
(See also, THC)

B

Biopsy
(See also, Diagnosis, cancer, and specific sites)
Frozen section, of childhood brain tumors, 307, 314
Incisional biopsy, 262–263
Needle biopsy, 159, 262–263
Percutaneous needle biopsy, 84, 86, 88, 89

Bladder cancer
And cigarette smoking, 118, 119
In the elderly patient, 337, 339–340
Incidence of, 23, 30, 42–43
Mortality of 23, 25, 29, 31
Secondary to melanoma, 137–139
Survival rates for, 36

Bleomycin
And mucocutaneous reactions to, 144–146, 150–152
For testicular cancer, 252

Bone cancer
Aneurysmal bone cyst, 83, 84
Chondrosarcoma, 67–69, 88
Diagnosis of, 66–89 (See also, Radiology, and specific modalities)
Ewing's tumor, 70–73, 79, 82, 86
Giant cell tumor, 67–71, 82, 84, 88
Incidence of, 30, 38
Management of, 66, 76, 79, 80, 84–89 (See also, specific modalities)
Metastatic disease in, 72–73, 86
Mortality of, 25, 31, 40–41
Myelocytic leukemia and, 72–73
Ollier's disease, 67–69
Osteosarcoma, 67–72, 83
Pathology of, 67, 84–85
Periosteal chondroma, 68–69
Periosteal reactions in, 72–73
Primary lesions in, 68–73, 86, 88
Radiologic evaluation of, 67–73
Secondary to breast cancer, 270
Secondary to leukemia, 171–172
Secondary to melanoma, 137–141
Staging of, 66, 68, 76, 80

Subject Index, 1980
Vol. 30, Nos. 1–6

A

Actinomycin-D
And mucocutaneous reactions to, 144–146, 150, 152
For ovarian cancer, 14
For rhabdomyosarcoma, 189
For testicular cancer, 252

Adriamycin
For acute lymphocytic leukemia (ALL), 170–171
Adverse reactions to, 170
And antiemetic for, 279–280
And mucocutaneous reactions to, 144–146, 148, 150–153
For ovarian cancer, 10, 14
For testicular cancer, 252

Aging, and cancer
Clinical considerations of, 338–339
Drug effects in, 344–345
Incidence of, 337, 339
Management of, 337–347 (See also, Radiation therapy)
Physiological changes in, 337–338, 341
Psychosocial problems of, 344–346
Sexual functions in, 344
Survival rates for, 338

Allopurinol
For acute lymphocytic leukemia (ALL), 164–165

American Cancer Society (ACS) cancer-related checkup guidelines
For breast cancer, 195–196, 224–231
For cervical cancer, 195–196, 215–223, 230–231
For colon and rectum cancer, 195–196, 208–215, 230–231
Cost-effectiveness analysis of, 197–198
Design issues of, 196–198
Experimental biases of, 234–236
Introduction to, 194
For lung cancer, 195–196, 199–207, 230–231
For populations *vs* individuals, 198
Previous ACS guidelines for, 199, 208, 215–216, 224
Rationale for, 205–206, 212–214, 219–223, 228–229
References for, 237–240
Risks and costs involved in, 202–205, 210–212, 218–219, 226–228
Summary of, 195–196, 229–234 (See also, specific sites and modalities)

Angiography, in diagnosis of childhood brain tumors, 308, 314

Anorexia, in the cancer patient, 110

Antiemetics
For cancer chemotherapy,
Prochlorperazine, 279, 283–284
THC (delta-9-tetrahydrocannabinol), 278–285
(See also, THC)

B

Biopsy
(See also, Diagnosis, cancer, and specific sites)
Frozen section, of childhood brain tumors, 307, 314
Incisional biopsy, 262–263
Needle biopsy, 159, 262–263
Percutaneous needle biopsy, 84, 86, 88, 89

Bladder cancer
And cigarette smoking, 118, 119
In the elderly patient, 337, 339–340
Incidence of, 23, 30, 42–43
Mortality of 23, 25, 29, 31
Secondary to melanoma, 137–139
Survival rates for, 36

Bleomycin
And mucocutaneous reactions to, 144–146, 150–152
For testicular cancer, 252

Bone cancer
Aneurysmal bone cyst, 83, 84
Chondrosarcoma, 67–69, 88
Diagnosis of, 66–89 (See also, Radiology, and specific modalities)
Ewing's tumor, 70–73, 79, 82, 86
Giant cell tumor, 67–71, 82, 84, 88
Incidence of, 30, 38
Management of, 66, 76, 79, 80, 84–89 (See also, specific modalities)
Metastatic disease in, 72–73, 86
Mortality of, 25, 31, 40–41
Myelocytic leukemia and, 72–73
Ollier's disease, 67–69
Osteosarcoma, 67–72, 83
Pathology of, 67, 84–85
Periosteal chondroma, 68–69
Periosteal reactions in, 72–73
Primary lesions in, 68–73, 86, 88
Radiologic evaluation of, 67–73
Secondary to breast cancer, 270
Secondary to leukemia, 171–172
Secondary to melanoma, 137–141
Staging of, 66, 68, 76, 80

Bone marrow transplantation, in cancer patients
In acute lymphocytic leukemia (ALL), 169, 172
In leukemia patients in remission, 45–52
Candidates for, 49, 51
Procedure for, 49–51
Risks of, 47–48, 50–51
Survival rates for, 46–47, 51

Brain (CNS) cancer
In children, 306–321
Classification of, 306–310, 314–315, 318
Astrocytoma, 306–310
Craniopharyngioma, 309
Ependymoma, 307, 309–310, 315, 318
Medulloblastoma, 306–307, 309–310, 314–315, 318
Detection and diagnosis of, 306–313, 317 (See also, specific modalities)
Clinical presentations of, 307–308, 311, 317
Ophthalmologic evaluation for, 308
Neurologic examination for, 311–314
Incidence of, 306–307, 309–310
Management of, 306, 310, 314–318
Postoperative care for, 315
Primary care for, 316–317
Use of steroids in, 315 (See also, specific treatment modalities)
New research in, 318
Prognosis of, 318
Recurrence assessment of, 317
Secondary to leukemia, 168–169, 171–172
Survival rates for, 36, 306, 309–310, 318
Tumor markers in, 318
Incidence of, 30, 38
Mortality of, 25, 31, 40–41
Secondary to melanoma, 137–139

Breast cancer
ACS checkup guidelines for, 195–196, 228–231
Classification of, 274
Detection and diagnosis of, 195–196, 224–231, 267–268, 272–276, 338
In Breast Cancer Detection Demonstration Projects (BCDDPs), 225–226
In the elderly patient, 338–339
In Health Insurance Plan of Greater New York (HIP) study, 224–226
Risks and costs of, 226–228
(See also, Mammography, and ACS cancer-related checkup guidelines)
High-risk factors for, 276–277
Hormonal therapy for, 99–100, 267–268, 270
Incidence of, 23, 30, 32, 42–43, 224, 274
Management of, 99–100, 126–128, 267–268, 270, 338
(See also, specific treatment modalities)
Metastases in, 267–268, 270
Mortality of, 23, 25, 28, 31, 33, 35, 41
And public attitudes towards, 94–95
Secondary to melanoma, 137–139
Staging of, 267–268
Survival rates for, 36, 224–225, 275

Bronchoscopy
In lung cancer, 203–204, 302

Busulfan
And mucocutaneous reactions to, 146–147

C

Carcinogens
Chemical carcinogenesis and gallbladder cancer, 333, 335–336
DES (diethylstilbestrol), 326–332 (See also, DES)
And immunotherapy, 288, 291
And radiation exposure, 202–205, 226–228, 272, 275–276

Cervical cancer
ACS checkup guidelines for, 195–196, 219–223, 230–231
In DES-exposed women, 326–332 (See also, DES)
Detection and diagnosis of, 195–196, 215–223, 230–231, 327–329 (See also, ACS cancer-related checkup guidelines)
Epidemiological studies of, 217–219
And herpes simplex, 288
Incidence of, 215, 326–327
Management of, 216–219, 327, 329 (See also, specific treatment modalities)
Natural history of, 216–219
Survival rates for, 215, 217–218, 327

Chemotherapy, cancer (See also, specific agents)
And alopecia, 143, 144, 146, 148, 150, 173, 175
Antiemetics for,
Prochlorperazine, 279, 283–284
THC (delta-9-tetrahydrocannabinol), 278–285
Application in HOME program, 183
For bone cancer, 86

And bone marrow transplants in leukemia patients, 45–46
For breast cancer, 268, 270
For childhood brain tumors, 310, 314–316, 318
And emotional reactions to, 106
And folinic acid rescue, 143, 148
For Hodgkin's disease, 267
For leukemia, 158, 164–176
For melanoma, 142, 268
Mucocutaneous reactions to, 143–157
Of alkylating agents, 146–147
Of antimetabolites, 147–150
Of antitumor antibiotics, 150–153
Of enzymes, 154
On gastrointestinal tract, 143–144
Of nitrosoureas, 154
On oral mucosa, 143–145, 148, 151
Of plant alkaloids, 153
On skin, 143–155
For ovarian cancer, 3, 4, 9–13
Public attitudes towards, 93
And radiation therapy, 144–146, 148, 150
And Reynaud's disease, 150, 152
For testicular cancer, 242, 252, 254, 267

Childhood cancer
Acute lymphocytic leukemia (ALL), 158–181 (See also, Leukemia)
Brain tumors, 306–321 (See also, Brain cancer)
Incidence of, 38
Mortality of, 38
Role of psychiatric oncology in, 111
Testicular cancer, 252, 254

Chlorambucil
And mucocutaneous reactions to, 146
For testicular cancer, 252

***Cis*-platinum**
Antiemetic for, 280
For testicular cancer, 252

Classics in Oncology
Adler on primary lung cancer, 294–297
Bennett's description of leukemia, 59–62
Lombard and Doering's epidemiologic studies, 115–122
Warren: Radiation effects on tissue, 350-355

Clinical trials, cancer
Advocation of randomized clinical trials, 53–54
Breast Cancer Detection Demonstration Projects (BCDDPs), 224–225, 228–229, 272–274
Health Insurance Plan of Greater New York (HIP) study, 224–229, 272–275
Of THC as antiemetic, 278–285

Colon and rectum cancer
ACS checkup guidelines for, 212–215
And cigarette smoking, 118–119
Detection and diagnosis of, 208–215 (See also, ACS cancer-related checkup guidelines, and specific modalities)
Duke's classification of, 211
In the elderly patient, 337, 339
Incidence of, 23, 30, 32, 208, 214
Mortality of, 23, 25, 28–29, 31, 33–34, 40–41
And public attitudes towards, 94–96
Secondary to melanoma, 137–139
Survival rates of, 36, 208, 213

Colorectal polyps
As precancerous lesions, 214

Cyclophosphamide
For acute lymphocytic leukemia (ALL), 170
Adverse reactions to, 170
And mucocutaneous reactions to, 144–148
For ovarian cancer, 10, 14
For testicular cancer, 252

Cytogenetics
In acute lymphocytic leukemia (ALL), 163–164

Cytology
For childhood brain tumors, 307
For leukemia, 159
For lung cancer, (See, Sputum cytology)
For vaginal cancer, 328

Cytosine arabinoside
For acute lymphocytic leukemia (ALL), 170–171
Adverse reactions to, 170
Mucocutaneous reactions to, 144

Cytoxan
And antiemetic for, 279–280
For rhabdomyosarcoma, 189

D

Dacarbazine
For metastatic melanoma, 142
And mucocutaneous reactions to, 154

Daunorubicin
For acute lymphocytic leukemia (ALL), 167
And mucocutaneous reactions to, 144–145, 151

DES (diethylstilbestrol)
Carcinogenesis of, 330–331
And DES-type drugs, 331
In exposed daughters,
And contraceptive advice to, 330
Cervical and vaginal clear cell adenocarcinomas,
Diagnosis of, 327–329
Etiology of, 330–331
Incidence of, 326–327
Management of, 327–329
Survival rates for, 327
And follow-up studies of, 326–327, 332
And psychosocial problems of, 331–332
And reproductive histories of, 328–330
In exposed mothers, 330
In exposed sons, 330
National Cooperative DES Adenosis (DESAD) Project, 326–327
Registry for Research on Hormonal Transplacental Carcinogenesis, 327, 332

Diagnosis, cancer
(See also, specific modalities, sites, and ACS cancer-related checkup guidelines)
Angiography, cerebral, 308, 314
Arteriography, 76–79, 262–263
Of bone cancer, 66–89
Bone marrow aspiration, 159
Of breast cancer, 195–196, 224–231, 267–268, 272–276, 338
Of carotid body tumors, 262–263
Cerebrospinal fluid (CSF) examination, 308, 314
Of cervical cancer, 216–223
In DES-exposed women, 327–329 (See also, DES)
Of childhood brain tumors, 306–313, 317
Of colon and rectum cancer, 208–215
Colposcopy, 328
Cytology, 159, 199–207, 307
Echoencephalography, 313
Electroencephalography (EEG), 308, 313
Electron microscopy, 88, 307
Of endometrial cancer, 16–20, 22
Of gallbladder cancer (case report), 333–334
Inferior venacavography (IVC), 249
Informing patient of, 104–105
Of leukemia, 159
Lumbar puncture, 314
Of lung cancer, 199–207, 295–300, 302
Lymphangiography (LAG), 249, 267
Of melanoma, 142
Of non-Hodgkin's lymphoma of spinal cord (case report), 123–125
Of ovarian cancer, 11–12, 101–102
Patient's reaction to, 105–107
Pneumoencephalography, 308
Radioisotope brain scans, 308, 313–314
Of sinus histiocytosis with lymphadenopathy (case report), 55–58
Of testicular cancer, 242–249, 267
Tomography, 74, 76–77
Ultrasound, 85–86, 101, 263
Of vaginal cancer, 327–329 (See also, DES)
Xeroradiography, 76–77

E

Editorials
NIH treatment regulations, 191–192
Surgical oncology as subspecialty, 63–64
Thirtieth anniversary, *Ca*, 356–357

Electron microscopy
In diagnosis of bone cancer, 88
In diagnosis of childhood brain tumors, 307

Endometrial cancer
And adenomatous hyperplasia, 16–17
Carcinoma in situ, 16–17
Detection and diagnosis of, 16–20, 22
In the elderly patient, 337, 339
High-risk conditions for, 17–22
And invasive cancer, 18–22
Management of, 18–21 (See also, specific treatment modalities)
Staging of, 18–19, 21–22

Epidemiology
And breast cancer screening studies, 274–276
In cervical cancer studies, 217–218
Study of individuals with and without cancer (classic), 115–122
In testicular cancer studies, 242

Esophageal cancer
And cigarette smoking, 118–119
Incidence of, 30, 42–43
Mortality of, 29, 31, 33, 40–41
Secondary to melanoma, 137–139
Survival rates for, 36

Etiology, cancer (See also, Carcinogens)
Chemically induced cancers, 288, 291
Of DES (diethylstilbestrol), 330–331 (See also, DES)
Spontaneous cancers, 288
Virally induced cancers, 287–288, 291

Eye cancer
Incidence of, 30
Mortality of, 31

F

5-Fluorouracil
Antiemetic for, 278, 280, 284
And mucocutaneous reactions to, 144–146, 148–150
For ovarian cancer, 10

G

Gallbladder cancer
And chemical carcinogenesis, 333, 335–336
Diagnosis of (case report), 333–334
Incidence of, 333, 335
Pathology of, 333, 335–336

H

Home Oncology Medical Extension (HOME) Program, 182–185

Hormonal treatment, in cancer
For breast cancer, 99–100, 267–268, 270
Estrogens and endometrial cancer, 21–22
(See also, DES)

Hydroxyurea
And mucocutaneous reactions to, 144–145, 154

Hypnotherapy, and cancer
Advantages of, 131, 135
Candidates for, 130–134
Case reports of, 132–136
Employers of, 130
Limitations of, 134–135
In psychological management of cancer pain, 130–136
Self-hypnosis, 131–134

Hypopharynx
Examination of, 322–323

I

Immunology
Human immunologic system,
Antibody response in, 286, 289–291
Cellular immune response in, 286, 289–291
NK cell immunity in, 286–287, 289–291 (See also, Immunotherapy)
Immunosuppression and cancer, 287

Immunotherapy
In acute lymphocytic leukemia (ALL), 169, 175
BCG vaccine, 291–292
And cancer immunoprevention, 291–293
And CEA, 292
And chemically induced cancer, 288, 291
And *Corynebacterium parvum*, 292
Future status of, 292–293
Monoclonal antibodies, 292–293
And interaction with lymphoid system, 290–291
Interferon, 292
Major approaches to, 289—292
Active nonspecific immunization, 289, 291–292
Active specific immunization, 289, 292
Immunity transfer, 289
For metastatic melanoma, 142
For ovarian cancer, 4–5
For testicular cancer, 254
And virally induced cancers, 287–288, 291

Interferon (See, Immunotherapy)

Interviews
Bone marrow transplants in leukemia patients, 45–52
Cancer and immunotherapy, 286–293
DES update, 326–332
Understanding the cancer patient, 103–112

K

Kidney cancer
Incidence of, 30, 38, 40–41
Mortality of, 25, 31, 40–41
Secondary to melanoma, 137–139
Survival rates for, 36

L

Laryngeal cancer
Examination for, 322–323
Incidence of, 30, 42–43
Mortality of, 31
Survival rates for, 36

Laryngoscopy
Description of, 322—323

L-asparaginase
For leukemia, 167, 170–171, 173
Adverse reactions to, 170

Leukemia
Acute lymphocytic leukemia (ALL) in children,
Bone marrow relapse in, 171–172
Bone marrow transplantation in, 49, 51, 169, 172
Classification of, 159, 161–164
And CNS involvement, 168–169, 171–172
Clinical features of, 164
Cytogenetics in, 163–164
Diagnosis of, 159
Financial support for patients with, 174–175
Immunotherapy in, 169, 175, 177
Incidence of, 158–159, 163
Infections in, 165, 167, 175–176
Leukemic cell blast crisis in, 158–159, 161, 167
Management of, 158–160, 164–177 (See also, specific treatment modalities)
Metastases in, 171–172
Outpatient care for, 167–168
Prognosis factors of, 164, 166, 177
Psychosocial support of patients with, 167–168, 173–175
Survival rates for, 158, 160, 164
Terminal deoxynucleotidyl transferase (TdT) in, 164
Testicular relapse in, 171–172
Acute myelomonoblastic leukemia (AMML), 159
Bennett's classic description of, 59–62
Bone marrow transplants in, 45–52, 169, 172 (See also, Bone marrow transplantation)
Incidence of, 23, 30, 32, 38, 40–41
Mortality of, 23, 25, 28–29, 31, 33, 35–36, 41, 158, 160, 164
Myelocytic leukemia and bone cancer, 72–73
Survival rates for, 36, 58, 160, 164

Liver cancer
Incidence of, 30
Mortality of, 31
Secondary to melanoma, 137–139, 141
Survival rates for, 36

Lung cancer
And cigarette smoking, 118–122
Detection and diagnosis of, 195–196, 199–207, 225–232, 295–300, 302 (See also, ACS cancer-related checkup guidelines)
In the elderly patient, 337–339
Historical review of, 294–300
Incidence of, 23, 30, 32, 199–202, 295–300, 303
Management of, 268, 303 (See also, specific treatment modalities)
Mortality of, 23–24, 28–29, 31, 33–34, 36, 40–41, 199–202, 297
Public attitudes towards, 96, 98
Secondary to melanoma, 137–141
And tuberculosis, 294–300

Lymphatic spread, of cancer
In melanoma, 137–139

Lymphomas
Burkitt's lymphoma, 228
Diagnosis of (case report), 123–124
Hodgkin's disease,
Management of, 267
Staging of, 267
Survival rates for, 36
Incidence of, 23, 30, 38, 40–41
Management of, 124–125 (See also, specific treatment modalities)
Mortality of, 23, 25, 31

M

Mammography
ACS guidelines for, 196, 228–229, 230–231
Benefits of, 224–227, 272–275
In Breast Cancer Detection Demonstration Projects (BCDDPs), 224–225, 228–229, 273–275
In Health Insurance Plan of Greater New York (HIP) studies, 224–229, 272–275
In high-risk patients, 276–277
Radiation dosage of, 226–227, 276
Risks and costs of, 226–228, 272, 275–276

Massive lymphadenopathy (SHML)
With sinus histiocytosis (case report), 55–58

Melphalan
And mucocutaneous reactions to, 146–147
For ovarian cancer, 10

6-Mercaptopurine
For acute lymphocytic leukemia (ALL), 170–171, 173, 176
Adverse reactions to, 170

Metastatic cancer (See also, specific sites)
Diagnosis of, 267–268
Management of, 267–268, 270
In melanoma, 137–142
Staging of, 266–267

Methotrexate
For acute lymphocytic leukemia (ALL), 168–173, 176–177
Adverse reactions to, 170
And antiemetic for, 279, 283
For childhood brain tumors, 316

For graft-*vs*-host disease in bone marrow transplants, 48
And mucocutaneous reactions to, 144, 146–149
For ovarian cancer, 10
For testicular cancer, 252

Mithramycin
And mucocutaneous reactions to, 150, 152–153

Mitomycin-C
And mucocutaneous reactions to, 153

N

Nasopharynx
Examination of, 322–323

National Institutes of Health (NIH)
Consensus Development Program treatment recommendations, 191–192

Nitrogen mustard
For childhood brain tumors, 316
And mucocutaneous reactions to, 147

Nitrosoureas, For childhood brain tumors, 316

Nutrition, and cancer
In the elderly patient receiving radiation therapy, 342–344

O

Opinions
AJC statement on cancer screening and staging, 324–325
Case for clinical trials, 53–54
Local excision for breast cancer, 126–128
THC as cancer chemotherapy antiemetic, 278–285
The usefulness of sperm banking, 186–188

Oral cancer
And cigarette smoking, 118–122
In the elderly patient, 342
Incidence of, 23, 30, 32, 42–43
Mortality of, 23, 31, 33–34, 36
Survival rates for, 36

Outpatient cancer care
Home Oncology Medical Extension Program (HOME), 182–185
For leukemic child, 167–168
Psychological benefits of, 109

Ovarian cancer
In children, 6, 10–14
Diagnosis of, 11–12, 101–102
Effects of ovarian tumor rupture, 3
Immunologic response in, 4–5
Incidence of, 23, 30, 42–43, 215
Management of, 2–14 (See also, specific treatment modalities)
Mortality of, 4, 9, 10, 23, 25, 28, 31, 36, 41
And peritoneal fluid profiles, 101–102
And pregnancy, 6, 13
Evaluating adnexal mass in, 6
Secondary to melanoma, 137–139
Staging of, 3–4

P

Pain control, and cancer
And THC (delta-9-tetrahydrocannabinol), 278–285 (See also, THC)
Use of hypnosis for, 130–136 (See also, Hypnotherapy)

Pancreatic cancer
And cigarette smoking, 118–119
Incidence of, 23, 30, 32
Mortality of, 23, 25, 28–29, 31, 33, 36, 40–41
Secondary to melanoma, 137–139
Survival rates for, 36

Papanicolaou smear
ACS guidelines for, 195, 219–223, 230–231
Benefits of, 216–219, 221
For endometrial cancer, 16
And public attitudes towards, 96
Risks and costs of, 218–219

Paragangliomas
Carotid body tumors (APUDomas),
Case histories of, 262
Diagnosis of, 260–264
Histology of, 260–262
History of, 260–261
Management of, 260–264 (See also, specific modalities)
Mortality of, 262
Classification of, 260–262
Incidence of, 260–263

Pathology, general
(See also, Staging, and specific sites)
Of bone cancer, 67, 84, 85
Of childhood brain tumors, 307–310, 314–315
Of gallbladder cancer, 333, 335–336
Of paragangliomas, 260–262
Of testicular cancer, 243–244, 247

Phenothiazines
In the elderly patient, 345
Prochlorperazine, 279, 283–284

Pituitary gland cancer
Secondary to melanoma, 137–139

Precancerous lesions
Adenomatous hyperplasia and endometrial cancer, 16–17
Colorectal polyps, 214

Prednisone
For acute lymphocytic leukemia (ALL), 167, 169–171, 173, 176
Adverse reactions to, 170
For childhood brain tumors, 316

Pregnancy, and cancer
In DES-exposed women, 328–330 (See also, DES)
And ovarian cancer, 6, 13

Procarbazine
For childhood brain tumors, 316
And mucocutaneous reactions to, 154

Prostatic cancer
And cigarette smoking, 118–119
In the elderly patient, 344
Incidence of, 23, 30, 32, 42–43
Mortality of, 23, 25, 29, 31, 33, 35, 36, 40
Secondary to melanoma, 137–139
Survival rates for, 36

Psychosocial problems, of cancer patients
And anorexia, 110
Attitudes towards treatment, 257–259
Cancer patient with significant psychiatric problems, 106–108
Children with cancer, 111, 315, 317
Coping mechanisms, 256–259
Of DES-exposed women, 331–332
Of the elderly patient, 344–347
And hypnosis, 130–136 (See also, Hypnotherapy)
Informing patient of cancer diagnosis, 104–107
Longterm survivors' concerns, 112
Psychiatric oncology, 103–105
Seminars for physicians on, 104
Psychologic profiles and cancer, 107
Role of primary physician in, 103–105
Sexual problems, 111–112, 344
Use of gestalt therapies, 131
Use of psychotropic drugs, 109–110

Public attitudes towards
Cancer curability, 92–93, 98
Cancer examinations, 92–94, 98
Cancer incidence, 92–93, 98 (See also, individual sites)
Cancer treatment, 93, 98
Cancer's warning signals, 93, 95

R

Radiation, low-level
And medical exposure, 202–205, 226–228, 272, 275–276

Radiation therapy
For bladder cancer, 337, 339, 340
For bone cancer, 85–86
And bone marrow transplants in leukemia patients, 45–46
For breast cancer, 268, 338–339
For carotid body tumors, 262
For cervical cancer, 327, 329
And chemotherapy, 144–145, 148, 150
For childhood brain tumors, 310, 314–315, 318–319
For colon and rectum cancer, 337, 339
In the elderly patient, 337–347
Clinical considerations of, 338–339
And informed consent, 345
Limitations to tolerance of, 337, 340
Long-term complications of, 343
Nutritional factors of, 342–344
Practical considerations of, 344–347
Response to, 339–341
And sexual function, 344
Treatment plans for, 341–342, 345 (See also, Aging, and cancer)
For endometrial cancer, 21, 337, 339
For leukemia, 168–169, 172
For lung cancer, 268, 337, 339
For oral cancer, 342
For ovarian cancer, 4, 9–13
For prostate cancer, 344
Public attitudes towards, 93
For testicular cancer, 250–253
For vaginal cancer, 327–329

Radioactive isotopes
In childhood brain tumors, 308, 313–314
In ovarian cancer, 3, 4, 6

Radioimmunoassay (RIA)
In testicular cancer, 243–247

Radiology
Chest x-rays for detection of lung cancer, 9, 195–207, 230–231
ACS guidelines for, 195–199, 205–207, 230–231
In diagnosis of bone cancer, 66–89
In diagnosis of childhood brain tumors, 313

In management of bone cancer, 66, 76, 79, 80, 85–89
(See also, Diagnosis, Bone cancer, and specific modalities)

Rhabdomyosarcoma
Management of (case report), 189–190

S

Screening, cancer
AJC statement on, 324–325
For breast cancer, 224–228, 272–276
In Breast Cancer Detection Demonstration Projects (BCDDPs), 224–225, 228–229, 273–274
In Health Insurance Plan of Greater New York (HIP) study, 224–229, 272–275
For cervical cancer, 215–223
For colon and rectum cancer, 208–214
For lung cancer, 199–207

Semustine
And antiemetic for, 278, 280, 284

Sigmoidoscopy
ACS guidelines for, 196, 208, 212–215, 230–231
Benefits of, 209
Risks and costs of, 210–212

Skin cancer
Incidence of, 23, 30, 137–139
Melanoma, malignant
Follow-up for, 140–142
Management of, 137, 142, 268 (See also, specific treatment modalities)
Metastatic patterns in, 137–142
Survival rates for, 36, 137
Mortality of, 23, 31, 35
And public attitudes towards, 95
Staging of, 266–267

Smoking, cigarettes
Incidence of, 44
And public attitudes towards, 96

Sperm banking, and cancer patients
Advantages of, 186
Candidates for, 186
Future developments in, 188
History of, 186–187
Legal implications of, 187–188
Methods of, 186–187

Sputum cytology
For lung cancer, 302–304
ACS guidelines for, 195–196, 199, 205–207, 230–231

Staging (See also, Opinions, and specific sites)
Of bone cancer, 66, 68, 76, 80
Of breast cancer, 267–268
Of childhood brain tumors, 307–310, 314–315
Of endometrial cancer, 18–19, 21–22
Of Hodgkin's disease, 267
Limitation of staging systems, 266
Of ovarian cancer, 3–4
Rational approach to, 266–271
Of skin cancer, 266
Of testicular cancer, 247–249, 253, 267

Statistics, cancer (See also, specific sites)
Incidence,
In black Americans, 39–44
In children, 38
By sex and site, 23, 30, 31–32
By stage, 37
By state, 32
Mortality,
Age-adjusted, 26–29
Around the world, 34–35
In black Americans, 39–41, 43
Leading causes of, 24
By site and sex, 23, 25–29, 31
By state, 33

Sterility, in cancer patients
Sperm banking for, 186–188 (See also, Sperm banking)

Stomach cancer
And cigarette smoking, 118–120
Incidence of, 30, 32, 42–43
Mortality of, 25, 28–29, 31, 33, 35, 40–41
Secondary to melanoma, 137–139
Survival rates for, 36

Stool gualac slide test
ACS guidelines for, 196, 208, 212, 230–231
Benefits of, 209–211
Procedure for, 212–213
Risks and costs of, 210–212

Surgery, cancer
For bone cancer, 79–80
For breast cancer, 270
Complications of, 127–128
Local excision of, 126–128
For carotid body tumors, 260–264
For cervical cancer, 216–219
In DES-exposed patient, 327, 329
For childhood brain tumors, 306, 310, 314–315

For endometrial cancer, 21
For lung cancer, 303
NIH treatment recommendations for, 191–192
For ovarian cancer, 2–8, 12
Public attitudes towards, 93
Surgical oncology as subspecialty, 63–64
For testicular cancer, 242, 249–253
For vaginal cancer in DES-exposed patient, 327, 329

T

Testicular cancer
In children, 252, 254
And cryptorchidism, 242–243
Diagnosis of, 242–247
Distant metastases in, 242, 252, 254
Epidemiology in, 242
Histology of, 244
Incidence of, 30, 242
Management of, 242, 249–254, 267
Mortality of, 25, 31
Pathologic classification of, 243–244, 247
Role of tumor markers in, 243–247, 254, 267
Secondary to leukemia, 171–172
Secondary to melanoma, 137–139
Staging of, 247–249, 253, 267

THC (delta-9-tetrahydrocannabinol)
As a cancer chemotherapy antiemetic,
Application of, 278–284
In different age populations, 280–281
Efficacy of, 279–285
History of, 278
Pharmacologic characteristics of, 280
Vs prochlorperazine, 279, 283–284
Side effects of, 279, 283
Studies of, 278–285
Toxicity of, 279–282, 284

Thyroid cancer
Incidence of, 30
Mortality of, 31
Secondary to melanoma, 137–139
Survival rates for, 36

Tomography
In bone cancer, 74, 76–77
CT scan in,
Bone cancer, 80–86
Brain tumors in children, 308, 311–314, 318
Metastatic melanoma, 142
Testicular cancer, 242, 249, 251, 254, 267

Tumor markers
In childhood brain tumors, 318
In testicular cancer, 243–247, 254, 267
Alphafetoprotein (AFP), 243–247
Human chorionic gonadotrophin (HCG), 243–247
Lactic dehydrogenase (LDH), 246–247
Pregnancy-specific β, glycoprotein (SP_1), 246–247

U

Ultrasound
In bone cancer, 85–86
In carotid body tumors, 263
In ovarian cancer, 101

Uterine cancer
Incidence of, 23, 30, 32, 42–43
Mortality of, 23, 25, 28, 31, 33, 35, 41
And public attitudes towards, 95–96
Secondary to melanoma, 137–139
Survival rates for, 36

V

Vaginal cancer
In DES-exposed women,
Diagnosis of, 327–329
Incidence of, 326–327
Management of, 327–329
Survival rates for, 327
And vaginal adenosis, 328–329
(See also, DES)

Vinblastine
And mucocutaneous reactions to, 153–154
For testicular cancer, 252

Vincristine
For acute lymphocytic leukemia (ALL), 167, 169–171, 173, 176
For childhood brain tumors, 316
And mucocutaneous reactions to, 144–145, 153–154
For ovarian cancer, 14
For rhabdomyosarcoma, 189–190

Vitamins, and cancer
Vitamin C, 101
Vitamin E, 100–101

X

Xeroradiography
In diagnosis of bone cancer, 76–77

Author Index, 1980
Vol. 30, Nos. 1–6

A

Adler, I. A., 295–301
Adrian, R. M., 143–157
Alpert, R., 256–259
Anderson, C. L., 302–304

B

Barber, H. R. K., 2–15, 101, 102
Barber, J., 130–136
Bean, G., 256–259
Bennett, J. H., 59–62
Brandt-Rauf, P. W., 333–336
Branwood, A. W., 333–336
Budman, D., 182–185
Burgert, E. O. Jr., 158–181

C

Carbone, P. P., 53–54
Cooper, S., 256–259
Crist, W., 55–58
Cronin, C. M., 283–285

D

Dearth, J., 55–58
Degnan, T., 182–185
de Santos, L. A., 66–91
DiPalma, J. R., 100, 101
Diener, J., 182–185
Doering, C.R., 115–122
Dumont, A. E., 101

E

Eddy, D., 194–240
Ertel, I. J., 306–321

F

Farr, H. W., 260–265
Fefer, A., 45–52
Frytak, S., 278–282

G

Garfinkel, L., 39–44
Gilchrist, G. S., 158–181
Gitelson, J., 130–136
Gunn, W. G., 337–347
Gusberg, S. B., 16–22

H

Herbst, A. L., 326–332
Holland, J., 103–112
Holleb, A. I., 191–192, 356–357
Hood, A. F., 143–157
Hoy, G., 189–190
Hunter, D., 55–58

J

Javadpour, N., 242–255

K

Kaplan, A. N., 99
Kelly, D., 55–58
Kennedy, B. J., 99, 100
Khan, A., 189–190
Kipnis, D., 256–259
Knight, I. A., 126–128

L

Lee, Y. N., 137–142
Lehman, J., 101
Lombard, H. L., 115–122
Luedke, D. W., 266–271
Luedke, S. L., 266–271

M

McCartney, J., 182–185
McKhann, C., 286–293
Moskowitz, M., 272–277

O

O'Connell, M., 182–185

P

Peterson, B. A., 99, 100
Poindexter, C. E., 39–44
Pollak, H., 100
Prager, D., 322–323

R

Rothman, C. P., 186–188
Routh, A., 123–125

S

Sallan, S. E., 283–285
Scanlon, E. F., 63–64,
Schulman, P., 182–185
Scott, J. H., 302–304
Shanker, P. S., 302–304
Silverberg, E., 23–38, 39–44
Sinks, L. F., 189–190
Skarin, A. T., 143–157
Smithson, W. A., 158–181

V

Vargas, M., 182–185
Vinciguerra, V., 182–185

W

Warren, S., 350–355